Drug Profile

Research programme: risperidone sustained-release - Critical Pharmaceuticals

Alternative Names: CP 018

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Critical Pharmaceuticals
Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 Nov 2017 No recent reports of development identified for research development in Schizophrenia in United Kingdom (Parenteral, Controlled release)
21 Nov 2013 Risperidone sustained release at the formulation development stage in United Kingdom
08 Oct 2008 Early research in Schizophrenia in United Kingdom (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com